Join our daily newsletter At The Bell to receive exclusive market insights
- Actinogen Medical (ACW) is set to expand its intellectual property portfolio with two new patents
- The healthcare stock filed the applications for its lead drug candidate, an Alzheimer’s treatment known as Xanamen
- Positively, the new submissions could extend the drug’s patent life protection up to 2040
- ACW’s first patent covers a process which seeks to improve cognitive function or treat cognitive decline in healthy adults
- Meanwhile, the second patent will protect Actinogen’s scale-up manufacturing process
- Looking ahead, Actinogen says it will continue to grow its patent portfolio and pursue opportunities to further advance its Xanamen treatment
- Actinogen closed steady following today’s news, with shares worth 2.2 cents each
Actinogen Medical (ACW) is set to expand its intellectual property portfolio with two new patents.
The healthcare stock filed the applications for its lead drug candidate, an Alzheimer’s treatment known as Xanamen. Positively, the new submissions could extend the drug’s patent life protection up to 2040.
ACW’s first patent covers a process which seeks to improve cognitive function or treat cognitive decline in healthy adults. The company opted to pursue a patent based on a phase one clinical trial, which indicated Xanamen could improve cognitive function compared to a placebo in elderly patients.
The second patent will protect Actinogen’s scale-up manufacturing process. It comes after the company worked with chemists and a Swiss-based contract development and manufacturing organisation (CDMO).
“Strengthening our IP portfolio and extending the patent life of protection over Xanamem is aligned with our broader commercialisation strategy,” Actinogen CEO and Managing Director Dr Bill Ketelbey said.
“The potential to treat cognitively healthy subjects … as well as treat those at risk of cognitive impairment, is a significant medical and commercial opportunity,” he continued.
“Actinogen remains focused on maintaining and extending the protection of Xanamem to maximise its commercial potential,” the CEO concluded.
Looking ahead, Actinogen says it will continue to grow its patent portfolio and pursue opportunities to further advance its Xanamen treatment.
Actinogen closed steady following today’s news, with shares worth 2.2 cents each.
